CommentPrecision oncology giveth and precision oncology taketh away
References (4)
- et al.
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
Lancet Oncol
(2016) - et al.
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a multiple basket study
Lancet Oncol
(2019)
There are more references available in the full text version of this article.
Cited by (2)
Genomic landscape of liquid biopsy for hepatocellular carcinoma personalized medicine
2021, Cancer Genomics and Proteomics
© 2019 Elsevier Ltd. All rights reserved.